KALV
KalVista·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KALV
Kalvista Pharmaceuticals, Inc.
A developer of protease inhibitors for the treatment of hereditary angioedema, and diabetic macular edema
200 Crossing Boulevard
Framingham
Massachusetts 01702
--
KalVista Pharmaceuticals, Inc., was incorporated in Delaware on March 26, 2004. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet needs. The company has used their insights into the chemistry and biology of proteases to develop oral therapies with high selectivity, potency and bioavailability, which the company believes will make them successful drugs for the treatment of diseases. The company has used these capabilities to develop novel small molecule plasma kallikrein inhibitors for hereditary angioedema (HAE). The Company is also in the preclinical development of a new oral factor XIIa (" Factor XIIa ") inhibitor program. The company is initially advancing this project to deliver next-generation HAE therapies, which also provides an opportunity to expand into other unmet high-demand indications in the future.
Earnings Call
Q3/2026
Estimate EPS-0.92
Actual EPS-0.92
Estimate Revenue14.38M
Actual Revenue13.69M
KalVista's Q3 2026: Contradictions Emerge on Access/Reimbursement Dynamics and Patient Burden/Adoption Trends
Nov 11,2025 08:27
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
KALV has released its 2026 Q3 earnings. EPS was reported at -0.92, versus the expected -0.92, meeting expectations. The chart below visualizes how KALV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KALV has released its 2026 Q1 earnings report, with revenue of 1.43M, reflecting a YoY change of NaN%, and net profit of -60.10M, showing a YoY change of -48.59%. The Sankey diagram below clearly presents KALV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
